These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2971 related items for PubMed ID: 16382061

  • 1. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    Breast International Group (BIG) 1-98 Collaborative GroupSenology Center of Eastern Switzerland, Kantonsspital, St. Gallen, and the Swiss Group for Clinical Cancer Research, Switzerland., Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.
    N Engl J Med; 2005 Dec 29; 353(26):2747-57. PubMed ID: 16382061
    [Abstract] [Full Text] [Related]

  • 2. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 3. Update of the BIG 1-98 Trial: where do we stand?
    Joerger M, Thürlimann B.
    Breast; 2009 Oct 10; 18 Suppl 3():S78-82. PubMed ID: 19914548
    [Abstract] [Full Text] [Related]

  • 4. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF.
    Semin Oncol; 2006 Apr 10; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [Abstract] [Full Text] [Related]

  • 5. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL.
    N Engl J Med; 2003 Nov 06; 349(19):1793-802. PubMed ID: 14551341
    [Abstract] [Full Text] [Related]

  • 6. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS, Johnson JR, Kelly R, Sridhara R, Williams G, Pazdur R.
    Clin Cancer Res; 2005 Aug 15; 11(16):5671-7. PubMed ID: 16115902
    [Abstract] [Full Text] [Related]

  • 7. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE.
    Semin Oncol; 2006 Apr 15; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [Abstract] [Full Text] [Related]

  • 8. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM.
    Expert Rev Anticancer Ther; 2007 May 15; 7(5):627-34. PubMed ID: 17492927
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM.
    Adv Ther; 2008 Dec 15; 25(12):1257-75. PubMed ID: 19096768
    [Abstract] [Full Text] [Related]

  • 11. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R.
    Eur J Surg Oncol; 2008 Jul 15; 34(7):746-55. PubMed ID: 18296017
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, Barghout V.
    Clin Breast Cancer; 2007 Jun 15; 7(8):608-18. PubMed ID: 17592673
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE, El-Ouagari K, Karnon J, Sofrygin O.
    Breast Cancer Res Treat; 2008 Apr 15; 108(3):375-87. PubMed ID: 17653859
    [Abstract] [Full Text] [Related]

  • 14. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
    Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE.
    Breast Cancer Res Treat; 2006 Oct 15; 99(3):295-300. PubMed ID: 16541302
    [Abstract] [Full Text] [Related]

  • 15. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P.
    J Clin Oncol; 2005 Aug 01; 23(22):5138-47. PubMed ID: 16009955
    [Abstract] [Full Text] [Related]

  • 16. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.
    J Clin Oncol; 2009 Nov 20; 27(33):5538-46. PubMed ID: 19786658
    [Abstract] [Full Text] [Related]

  • 17. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH, Johnson JR, Li N, Chen G, Pazdur R.
    Clin Cancer Res; 2002 Mar 20; 8(3):665-9. PubMed ID: 11895893
    [Abstract] [Full Text] [Related]

  • 18. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Koeberle D, Thuerlimann B.
    Expert Rev Anticancer Ther; 2006 Jan 20; 6(1):5-10. PubMed ID: 16375638
    [Abstract] [Full Text] [Related]

  • 19. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
    Cancer; 2003 Nov 01; 98(9):1802-10. PubMed ID: 14584060
    [Abstract] [Full Text] [Related]

  • 20. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
    Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D.
    J Clin Oncol; 2008 Apr 20; 26(12):1948-55. PubMed ID: 18332475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 149.